MaxCyte and Be Biopharma Collaborate to Develop Engineered B Cell Medicines (BCMs)
Shots:
- MaxCyte and Be Biopharma have entered into a strategic platform license (SPL) for the development of Be Bio’s engineered B Cell medicines (BCMs)
- Under the collaboration, Be Bio gains non-exclusive research, clinical & commercial rights to leverage MaxCyte’s Flow Electroporation technology & ExPERT platform while MaxCyte will receive annual licensing fees & program-associated revenue
- The ExPERT platform, based on Flow Electroporation technology, is developed for complex cell engineering with high transfection efficiency, scalability, and enhanced functionality
Ref: MaxCyte | Image: MaxCyte
Related News:- MaxCyte Signs a Strategic Platform License with Curamys for Cell and Gene Therapies to Treat Rare Intractable Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
